Lazertinib + Amivantamab for Non-Small Cell Lung Cancer
(Chrysalis-2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests Lazertinib and Amivantamab for patients with advanced lung cancer with specific mutations. Lazertinib stops cancer cell growth, while Amivantamab helps the immune system kill these cells.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, you should discuss your current medications with the study team to ensure they don't interfere with the trial treatments.
Is the combination of Lazertinib and Amivantamab safe for humans?
The combination of Lazertinib and Amivantamab has been tested in clinical trials for non-small cell lung cancer, and the safety profile was generally consistent with previous experiences of each drug alone, with only 4% of patients experiencing severe side effects. No new safety concerns were identified.12345
What makes the drug combination of Lazertinib and Amivantamab unique for treating non-small cell lung cancer?
The combination of Lazertinib and Amivantamab is unique because it targets both EGFR and MET mutations, which are common in non-small cell lung cancer, and is effective even after resistance to other treatments like osimertinib. This combination offers a novel approach by using a bispecific antibody (Amivantamab) and a third-generation EGFR inhibitor (Lazertinib) to improve outcomes for patients who have relapsed on standard therapies.14567
What data supports the effectiveness of the drug combination of Lazertinib and Amivantamab for treating non-small cell lung cancer?
Research shows that the combination of Lazertinib and Amivantamab is effective in treating non-small cell lung cancer, especially in patients who have relapsed after using osimertinib. In studies, this combination demonstrated antitumor activity and improved response rates, with some patients experiencing a median progression-free survival of up to 11.1 months.14567
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
This trial is for adults with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations. Participants may have had previous treatments like chemotherapy or EGFR inhibitors, but must not have uncontrolled illnesses, active infections, severe gastrointestinal issues, or untreated brain metastases. They should be able to swallow pills and comply with study requirements.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Lazertinib and Amivantamab in various combinations, with some cohorts also receiving platinum-doublet chemotherapy.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- Amivantamab
- Carboplatin
- Lazertinib
- Pemetrexed
Amivantamab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University